Drug Profile
Research programme: antibacterials - Indel Therapeutics
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Indel Therapeutics
- Class Small molecules
- Mechanism of Action Alpha kinase inhibitors; Pyruvate kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Gram-negative infections; Leishmaniasis; Malaria; Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Gram-negative-infections in Canada
- 16 Jul 2016 No recent reports of development identified for research development in Leishmaniasis in Canada
- 16 Jul 2016 No recent reports of development identified for research development in Malaria in Canada